Kratom, a botanical product sold in gas stations and smoke shops, and its potent cousin 7-hydroxymitragynine, or 7-OH, are at the center of a fast-moving public health and political fight. For years, kratom remained federally legal in the United States, protected by a loose coalition of users, retailers, and advocates who described it as a natural way to manage pain, anxiety, and opioid withdrawal. Now, rising reports of addiction, withdrawal, and death are prompting a crackdown—one that is unfolding unevenly across federal agencies, state legislatures, and local clinics.

The Drug Enforcement Administration plans to ban 7-OH, according to Wired, a move that would target the most opioid-like compound found in or derived from kratom. In Missouri, officials banned 7-OH sales after a settlement with two companies, the News-Leader reported. And Health and Human Services Secretary Robert F. Kennedy Jr. is cracking down on what USA Today called 'hippie heroin' in 7-OH, even as kratom addicts and advocates say the action does not go far enough. The New York Times reported that kratom, an addictive gas station drug, has found allies in Trump's Cabinet—a reminder that the politics of the plant are as complicated as its pharmacology.

What kratom and 7-OH are—and why they are everywhere

Kratom comes from the leaves of Mitragyna speciosa, a tree native to Southeast Asia. Its leaves contain mitragynine and 7-hydroxymitragynine, compounds that interact with opioid receptors. Traditional leaf powder is relatively mild; concentrated extracts and products marketed as 7-OH are far more potent. Vox described the boom as 'the rise of gas station opioids,' a phrase that captures how quickly these products moved from herbal supplement shelves to convenience-store counters and smoke-shop displays.

NPR reported that kratom and 7-OH can feel like 'a miracle' to some users—and can also be addictive. That duality runs through the entire story. Supporters say kratom helps people avoid illicit opioids or manage chronic pain. Critics, including Brandeis opioid researcher Andrew Kolodny, describe growing risks. Health Affairs called the rise of kratom 'a dangerous and familiar pattern,' invoking the early warning signs of the opioid epidemic: easy access, aggressive marketing, limited oversight, and a public health system that often reacts after harm has spread.

The human cost: withdrawal, rehab, and family trauma

Addiction clinics are seeing rising cases of kratom and 7-OH withdrawal, STAT reported. The clinical picture can include anxiety, insomnia, muscle aches, gastrointestinal distress, and intense cravings—symptoms that are familiar to anyone who has treated opioid dependence. Local news outlets have put faces to the trend. The Detroit News and MSN told the story of a Michigan mother hooked on kratom and her traumatic road to recovery. WTOL reported on an Adrian woman who said a legal 7-OH product sold in smoke shops led her to addiction and rehab. KOMU captured a Missouri family's struggle with the phrase 'It costs peace.' An addiction doctor told The T&D that patients often underestimate the risk because the products are legal and marketed as natural.

'It costs peace,' a Missouri family told KOMU, describing the toll of kratom addiction.

In Florida, The Ledger reported that concentrated forms of kratom are bringing grim stories of addiction to Polk County. CBS Chicago reported that Feel Free, a kratom drink, is gaining popularity despite growing concerns about addiction, health impact, and death. The New York Post used the arrest of Brandon Clarke for kratom possession to explain the drug to a national audience. Together, these local and national accounts show how a substance that is often marketed as natural and legal can still produce serious dependence and family disruption.

Regulation vs. treatment: the policy fight

The federal response is moving on multiple tracks. The DEA's planned ban on 7-OH would mark one of the most significant federal actions against a kratom-related product since the agency considered scheduling kratom itself years ago. That earlier effort collapsed after public backlash and lobbying by advocates, who argued that banning the leaf would harm people who use it responsibly and would push users toward illicit opioids. The current crackdown is narrower, focusing on 7-OH, the compound that regulators and researchers say behaves most like a conventional opioid.

But researchers at the University of Maryland argue that a ban is not enough. In work highlighted by Yahoo, they said that fighting kratom addiction requires treatment, surveillance, and public education—not simply prohibition. That view is echoed by addiction specialists and by the Health Affairs analysis, which warns that removing a product from shelves without expanding care can leave dependent users with nowhere to turn. The Missouri settlement shows how states may act faster than Washington: after the agreement with two companies, Missouri moved to ban 7-OH sales, according to the News-Leader. Yet the state's experience also illustrates the limits of a patchwork approach, with users crossing borders or turning to online sellers.

Different outlets frame the story differently. NPR emphasizes the 'miracle' and addiction duality. STAT and Health Affairs focus on clinical consequences and the risk of repeating the opioid epidemic. Vox and Wired center the policy and pharmacology of gas-station opioids. Local outlets—the Detroit News, WTOL, KOMU, The Ledger, azcentral, and the News-Leader—document the human cost in Michigan, Missouri, Florida, and Arizona. USA Today and the New York Times examine the political coalition around kratom, including allies in Trump's Cabinet and Kennedy's push against 7-OH. CBS Chicago tracks the commercial side, where products like Feel Free are building a consumer market even as warnings grow.

What comes next

The central question is whether the United States can regulate potent kratom products without punishing people who use the leaf responsibly—and without repeating the mistakes of the opioid era. A 7-OH ban may reduce access to the riskiest products, but clinics say they are already seeing withdrawal cases that require medically supervised care. Researchers want better data on how many people use kratom, how often they progress to 7-OH, and what happens when products are pulled from shelves. Advocates warn that a broad crackdown could drive users underground. Regulators counter that the current market is too wild to leave alone.

For now, kratom remains federally legal, 7-OH faces a DEA ban and state-level restrictions, and families across the country are navigating a legal gray market that can feel like a miracle and a trap at the same time. The next phase will test whether policy can catch up to the gas station shelf—and whether treatment systems can catch the people left in its wake.